+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, and Cervical Cancer), Drug Class Type, Distribution, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4896719
  • Report
  • April 2022
  • Region: Global
  • 181 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
The Global Oncology Drugs Market size was estimated at USD 114.02 billion in 2021, USD 122.71 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.80% to reach USD 178.95 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Oncology Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Drug Class Type, the market was studied across Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Distribution, the market was studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Oncology Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oncology Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Oncology Drugs Market, including AbbVie Inc., Ability Pharma, Acadia Pharmaceuticals Inc., Aegerion Pharmaceuticals Inc., Amgen Inc., ARIAD Pharmaceuticals, Inc., Aslan Pharmaceuticals Ltd.,, Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Athenex, Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals Industries.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Oncology Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Oncology Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Oncology Drugs Market?
6. What is the market share of the leading vendors in the Global Oncology Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Oncology Drugs Market?
Frequently Asked Questions about the Global Oncology Drugs Market

What is the estimated value of the Global Oncology Drugs Market?

The Global Oncology Drugs Market was estimated to be valued at $114.0 Billion in 2021.

What is the growth rate of the Global Oncology Drugs Market?

The growth rate of the Global Oncology Drugs Market is 7.8%, with an estimated value of $179.0 Billion by 2027.

What is the forecasted size of the Global Oncology Drugs Market?

The Global Oncology Drugs Market is estimated to be worth $179.0 Billion by 2027.

Who are the key companies in the Global Oncology Drugs Market?

Key companies in the Global Oncology Drugs Market include AbbVie Inc., Ability Pharma, Acadia Pharmaceuticals Inc., Aegerion Pharmaceuticals Inc., Amgen Inc., ARIAD Pharmaceuticals, Inc., Aslan Pharmaceuticals Ltd.,, Aspen Pharmacare Holdings Limited and AstraZeneca PLC.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer across the globe
5.1.1.2. Surge in global geriatric population
5.1.1.3. Increase in government expenditures on healthcare
5.1.1.4. Elevated development of Biosimilar in Oncology arena
5.1.2. Restraints
5.1.2.1. Adverse effects associated with the use of cancer drugs
5.1.3. Opportunities
5.1.3.1. Untapped emerging economies
5.1.3.2. Increase in number of pipeline drugs
5.1.4. Challenges
5.1.4.1. High cost of the drug
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Oncology Drugs Market, by Indication
6.1. Introduction
6.2. Bladder Cancer
6.3. Breast Cancer
6.4. Cervical Cancer
6.5. Colorectal Cancer
6.6. Esophagus Cancer
6.7. Kidney Cancer
6.8. Liver Cancer
6.9. Lung Cancer
6.10. Prostate Cancer
6.11. Stomach Cancer
7. Oncology Drugs Market, by Drug Class Type
7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
8. Oncology Drugs Market, by Distribution
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Oncology Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Oncology Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Oncology Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.2. Ability Pharma
13.3. Acadia Pharmaceuticals Inc.
13.4. Aegerion Pharmaceuticals Inc.
13.5. Amgen Inc.
13.6. ARIAD Pharmaceuticals, Inc.
13.7. Aslan Pharmaceuticals Ltd.,
13.8. Aspen Pharmacare Holdings Limited
13.9. Astellas Pharma Inc.
13.10. AstraZeneca PLC
13.11. Athenex, Inc.
13.12. Bayer AG
13.13. Boehringer Ingelheim GmbH
13.14. Bristol-Myers Squibb Company
13.15. Celgene Corporation
13.16. Eli Lilly and Company
13.17. F. Hoffmann-La Roche Ltd.
13.18. Gilead Sciences Inc
13.19. GlaxoSmithKline PLC
13.20. Johnson & Johnson Services, Inc.
13.21. Merck & Co., Inc.
13.22. Novartis International AG
13.23. Pfizer Inc.
13.24. Takeda Pharmaceutical Company Limited
13.25. Teva Pharmaceuticals Industries
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ONCOLOGY DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2027
FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, 2019-2027 (USD BILLION)
FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2021 VS 2027 (%)
FIGURE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2027
FIGURE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2019-2027 (USD BILLION)
FIGURE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2019-2027 (USD BILLION)
FIGURE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD BILLION)
FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2027
FIGURE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 45. AMERICAS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. BRAZIL ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. CANADA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. MEXICO ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. CHINA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. INDIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. INDONESIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. JAPAN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. TAIWAN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. THAILAND ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. FRANCE ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. GERMANY ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. ITALY ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 67. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. QATAR ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. RUSSIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 71. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 72. SPAIN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 73. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 74. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 75. GLOBAL ONCOLOGY DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL ONCOLOGY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 77. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ONCOLOGY DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ONCOLOGY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 25. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 27. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 30. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 32. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 35. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 37. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 40. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 42. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 45. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 47. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 50. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 52. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS TYPE, 2019-2027 (USD BILLION)
TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 56. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 58. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 63. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 66. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 67. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 68. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 70. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 72. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 73. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 75. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD BILLION)
TABLE 76. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 78. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 79. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 81. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 82. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 83. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 84. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 86. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 87. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 88. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 89. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 91. AMERICAS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 93. BRAZIL ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 94. CANADA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 95. MEXICO ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 96. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 97. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 98. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 99. CHINA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 100. INDIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 101. INDONESIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 102. JAPAN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 103. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 104. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 105. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 106. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 107. TAIWAN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 108. THAILAND ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 110. FRANCE ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 111. GERMANY ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 112. ITALY ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 113. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 114. QATAR ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 115. RUSSIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 116. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 117. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 118. SPAIN ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 119. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 120. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 121. GLOBAL ONCOLOGY DRUGS MARKET: SCORES
TABLE 122. GLOBAL ONCOLOGY DRUGS MARKET: BUSINESS STRATEGY
TABLE 123. GLOBAL ONCOLOGY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 124. GLOBAL ONCOLOGY DRUGS MARKET: RANKING
TABLE 125. GLOBAL ONCOLOGY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 126. GLOBAL ONCOLOGY DRUGS MARKET: MERGER & ACQUISITION
TABLE 127. GLOBAL ONCOLOGY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 128. GLOBAL ONCOLOGY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 129. GLOBAL ONCOLOGY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 130. GLOBAL ONCOLOGY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 131. GLOBAL ONCOLOGY DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Ability Pharma
  • Acadia Pharmaceuticals Inc.
  • Aegerion Pharmaceuticals Inc.
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Aslan Pharmaceuticals Ltd.,
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Athenex, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries
Note: Product cover images may vary from those shown

Loading
LOADING...